Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cellek, S.
Right arrow Articles by Foxwell, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cellek, S.
Right arrow Articles by Foxwell, N. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:212-219, 2005
© 2005 by the American Diabetes Association, Inc.

Nitrergic Neurodegeneration in Cerebral Arteries of Streptozotocin-Induced Diabetic Rats

A New Insight into Diabetic Stroke

Selim Cellek1, Patrick N. Anderson2, and Neale A. Foxwell1

1 Wolfson Institute for Biomedical Research, University College London, London, U.K
2 Department of Anatomy and Developmental Biology, University College London, London, U.K


   ABSTRACT
TOP
 ABSTRACT
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Although autonomic neuropathy is recognized as an independent risk factor for stroke in diabetes, the mechanism by which autonomic nerves are involved in this pathology is unknown. Parasympathetic (cholinergic) nerves of the autonomic nervous system are known to innervate and to cause relaxation of cerebral arteries by releasing nitric oxide (NO); hence, they are called nitrergic nerves. However, the effect of diabetes on nitrergic nerves is unknown. Here, we show that perivascular nitrergic nerves around the cerebral arteries degenerate in two phases in streptozotocin-induced diabetic rats. In the first phase, perivascular nitrergic nerve fibers remain intact while they lose their neuronal NO synthase content. This phase is reversible with insulin treatment. In the second phase, nitrergic cell bodies in the ganglia are lost via apoptosis in an irreversible manner. Throughout the two phases, irreversible thickening of the smooth muscle layer of cerebral arteries is observed. This is the first demonstration of nitrergic degeneration in diabetic cerebral arteries, which could elucidate the link between diabetic autonomic neuropathy and stroke.

Diabetes is associated with an increased risk of cardiovascular disease—in particular, coronary heart disease and stroke (1–4). Mortality from stroke has been demonstrated to be increased significantly by diabetes (2). Hypertension, smoking, and dyslipidemia are major risk factors for the occurrence of strokes in diabetic patients (4). Recently, autonomic neuropathy has been described as a significant independent risk factor for diabetes-related stroke (5). However, the mechanism by which autonomic neuropathy might be involved in the pathogenesis of stroke has not been elucidated.

Autonomic nerves are known to innervate cerebral arteries (6). Parasympathetic (cholinergic) nerves, which contain neuronal nitric oxide synthase (nNOS), have been shown in the walls of cerebral blood vessels in many species, including humans (7). These nerves are now called "nitrergic nerves" (8) and have been shown to originate mainly from the sphenopalatine ganglia (9–12). Stimulation of perivascular nitrergic nerves has been demonstrated to relax the cerebral arteries by the action of nitric oxide (NO) and to increase the cortical blood flow (6,13–15). It is not known whether the nitrergic nerves in the cerebral vasculature are affected during diabetes. We therefore investigated the effect of diabetes on the morphology and nNOS content of these nerves in the cerebral arteries of streptozotocin (STZ)-induced diabetic rats.


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Induction of diabetes.
Male Wistar rats (225–250 g) were treated with STZ (75 mg/kg i.p.) or vehicle (saline) as described previously (16,17). Hyperglycemia was defined as a nonfasting blood glucose concentration >20 mmol/l. Insulin was administered 8 and 12 weeks after STZ injection using sustained-release insulin rods (7 mm, ~2 units/day; LinBit, LinShin Canada, Toronto, ON, Canada). Rats were killed 4, 8, 12, 16, and 20 weeks after STZ injection with an overdose of pentobarbitone, and their blood, cerebral arteries, and sphenopalatine ganglia were collected. Some of the animals were perfused through the heart with 4% paraformaldehyde before collecting the cerebral arteries and ganglia. Blood was centrifuged to obtain serum for measuring glucose using a Reflolux-S Glucometer (Boehringer Mannheim, Mannheim, Germany). The blood vessels and ganglia collected from unperfused animals were frozen in liquid nitrogen for protein quantification using Western blotting. The tissues from perfused animals were further fixed in 4% paraformaldehyde for immunohistochemistry. All animal experiments were conducted according to the rules outlined by the Home Office, Animals (Scientific Procedures) Act 1986 (project number 70/05161).

Immunohistochemistry.
After fixation in 4% paraformaldehyde for 48 h at room temperature, the tissues were transferred into 30% sucrose in phosphate buffer and kept at 4°C overnight. The samples were then frozen in OCT compound (Raymond A. Lamb, Ltd., East Sussex, U.K.), and serial cryosections at 10- to 20-µm intervals were obtained using a cryostat (–18°C; 2800 Frigocut-E; Leica, Heidelberg, Germany). The sections were dried on gelatin-coated slides for 2 h at room temperature and then incubated with PBS containing 0.1% Triton X-100 and 5% of the serum of the species from which the secondary antibody was obtained. Then the slides were incubated with antibodies against nNOS (raised in sheep, K205 [18]; 1:2,000), vesicular acetylcholine transporter (VAChT) (Chemicon; 1:100), PGP9.5 (Chemicon; 1:1,000), or smooth muscle specific {alpha}-actin (Sigma; 1:1,000) overnight followed by detection with the following fluorescent conjugated secondary antibodies: fluorescein isothiocyanate (FITC)-conjugated anti-sheep IgG raised in donkey (Chemicon; 1:250) for nNOS, rhodamine-conjugated anti-goat IgG raised in donkey (Chemicon; 1:250) for VAChT, FITC-conjugated anti-rabbit IgG raised in goat (Chemicon; 1:250) for PGP9.5, and FITC-conjugated anti-mouse IgG raised in goat (Chemicon; 1:250) for {alpha}-actin. The sections were covered with coverslips after addition of VectaShield mounting medium containing 4',6-diamindino-2-phenylindole dihydrochloride (DAPI) (Vector) to visualize the nuclei. No immunostaining was observed when the primary antibodies were omitted. Tdt-mediated dUTP nick-end labeling (TUNEL) staining was performed according to the manufacturer’s instructions (Roche).

Image analysis.
The images were obtained using a laser-scanning confocal microscope (TCS-DMRE; Leica). Image analysis was performed using Scion Image software (version beta 4.02; Scion) and Leica Confocal Software (Version 2.00, build0871; Leica) as described previously (17,19).

The immunostaining density of perivascular nerve fibers was measured as the mean amplitude of fluorescence per 1 µm2 in areas occupied by nerve fibers. To avoid day-to-day variation in fluorescence intensity, several sections from different experimental groups were immunostained and analyzed in the same batch on the same day. The laser intensity and gain functions were set according to the control tissue; thereafter, these settings were applied to all sections from all experimental groups within the same batch. The results were expressed as percentage of control to avoid the variation between different batches.

nNOS+ cell bodies in the ganglia were counted manually in a blinded fashion, and the area occupied by the counted cells was measured to give the number of cells per 100,000 µm2.

The thickness of smooth muscle layer was determined in sections immunostained with an antibody raised against smooth muscle-specific {alpha}-actin. The distance covered by the smooth muscle cells was measured in 10 random areas in each section using the Leica Confocal Software. The measurements were then pooled for each group.

Western blotting.
The frozen tissues were pulverized using a stainless steel pestle and mortar on dry ice, homogenized in 100 µl homogenization buffer (20 mmol/l HEPES, pH 7.2, 1 mmol/l EDTA, 0.2 mol/l sucrose, 5 mmol/l dithiothreitol, 0.1 mmol/l phenylmethylsulfonyl fluoride, 20 µg/ml leupeptin and soya bean trypsin inhibitor, pepstatin, E-64, bestatin, aprotinin, and 5 µg/ml 3,4-dichloroisocoumarin) and centrifuged at 13,000g for 30 min at 4°C as described previously (16,17). The protein concentration in the supernatant was measured, and equal amounts of protein were run on 8% polyacrylamide SDS gels and then transferred to nitrocellulose membranes. The blots were incubated overnight with monoclonal nNOS antibody (raised against the 10951-289 region of human nNOS; Transduction Laboratories; 1:2,000) and then with horseradish peroxidase-conjugated anti-mouse IgG (Vector Laboratories; 1:2,000) for 2 h. The reactive bands were detected with a luminol-based kit. The optimal X-ray exposure was selected and scanned, and the density of each band corresponding to nNOS was measured using Scion Image software. The density of each band was then expressed as a percentage of the band in that gel from a control (nondiabetic) animal. Nondiabetic rat brain cytosol was used as a positive control.

Presentation of the results.
Nondiabetic age-matched animals that were injected with saline and killed at the end of 20 weeks are referred to as the control group. STZ-induced diabetic rats without any insulin treatment are referred to as "4w," "8w," "12w," "16w," and "20w," where they were killed at the end of 4, 8, 12, 16, and 20 weeks after STZ injection, respectively. STZ-induced diabetic animals with insulin treatment are referred to as the "20/8 group" and "20/12 group," where they were killed at the end of 20 weeks after STZ injection and they received insulin for the last 8 and 12 weeks, respectively.

Statistical analysis.
Results are expressed as means ± SE from a number (n) of animals. Statistical analyses were performed using Prism software (version 3.0; GraphPad Software). Data were compared by one-way ANOVA with Dunnett’s or Bonferroni’s post-test. P values of <0.05 were considered significant.


   RESULTS
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Body weight and serum glucose.
The STZ-injected rats, which did not receive any insulin treatment, lost weight or did not gain as much weight as control animals (Fig. 1A), and their serum glucose concentrations were significantly higher (Fig. 1B). The animals that received insulin treatment beginning 8 or 12 weeks after STZ injection gained weight (Fig. 1A), and their serum glucose concentrations decreased to control levels shortly after initiation of insulin treatment (Fig. 1B).



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1. Delayed insulin treatment normalizes body weight and serum glucose levels. The weight (A) and serum glucose (B) of rats during 20 weeks of diabetes are shown. STZ was injected at week 0. The control group ({blacksquare}), diabetic group ({square}), and diabetic groups with insulin treatment begun at the 8th (•) and 12th ({circ}) week are shown. Data are means ± SE.

 
nNOS immunofluorescence in cerebral perivascular nerves.
In pilot studies, we compared nNOS immunofluorescence in different parts of the cerebral vasculature, such as the anterior, middle, and posterior cerebral arteries and the basilar artery, in nondiabetic rats. Because the middle cerebral artery showed the most consistent immunostaining (not shown), it was used for the rest of the study. In control (nondiabetic) animals, nNOS immunostaining was observed in the nerve fibers surrounding the middle cerebral artery (Fig. 2A and F). These fibers run irregularly around the arterial wall. The density of nNOS+ fibers decreased gradually during 20 weeks of diabetes (Fig. 2B and C and Fig. 3). By 20 weeks, very few or no nNOS+ fibers were observable (Fig. 2C). In the 20/8 (8 weeks of insulin) group, the density nNOS+ fibers were similar to those in the 20w group (Fig. 2D and Fig. 3). There was no significant difference between the control and 20/12 group (12 weeks of insulin) (Fig. 2E and Fig. 3).



View larger version (112K):
[in this window]
[in a new window]
  		FIG. 2. Insulin treatment started at the 8th week rescues nitrergic nerve fiber loss. nNOS immunostaining in the middle cerebral arteries from control (A), 12w (B), 20w (C), 20/8 (D), and 20/12 (E) groups is shown. nNOS (green; F) and VAChT (red; G) were colocalized in the nerve fibers around the middle cerebral artery (overlay; H). Control (F–H), 12w (I), 20w (J), 20/8 (K), and 20/12 (L) are shown. Note that some VAChT+ nerve fibers were negative for nNOS in the 12w group (white arrow). Scale bar = 100 µm.

 


View larger version (45K):
[in this window]
[in a new window]
  		FIG. 3. VAChT and PGP9.5 staining reveals nitrergic degeneration after 12 weeks. nNOS ({blacksquare}), VAChT ({square}), and PGP9.5 ({cjs2110}) immunostaining of middle cerebral arteries is shown. Immunostaining density was measured as the mean amplitude of fluorescence per 1 µm2 in areas occupied by nerve fibers and expressed as the percentage of the control in the same batch. Data are means ± SE. *P < 0.05, significantly different from control; ANOVA followed by Dunnett’s test.

 
nNOS and VAChT colocalization.
Because nNOS and the cholinergic nerve marker, VAChT, are known to be colocalized in parasympathetic perivascular nerve fibers, we studied VAChT immunostaining throughout 20 weeks of diabetes. In control animals, all of the nNOS+ nerves were also positive for VAChT (Fig. 2F). Diabetic animals at 4, 8, and 12 weeks showed a gradual decline in nNOS immunostaining, whereas VAChT staining remained unchanged (Fig. 3). At 12 weeks, VAChT+ but nNOS– nerve fibers were visible (Fig. 2I), but thereafter, as demonstrated by the 16w and 20w groups, VAChT staining declined rapidly (Fig. 2J and Fig. 3). The VAChT immunostaining showed significant recovery in the 20/12 group but not in the 20/8 group (Fig. 2K and L and Fig. 3).

PGP9.5 immunostaining.
To ascertain the change in the total amount of nerve fibers, we immunostained the middle cerebral artery sections with a nonspecific neuronal marker, PGP9.5. The immunostaining density with PGP9.5 did not show any significant change until 16 weeks, after which it gradually decreased and reached a significant level at the end of 20 weeks. The 20/8 group had a similar decline. The 20/12 group, however, showed a significant recovery of PGP9.5 immunostaining (Fig. 3).

Sphenopalatine ganglia.
To determine whether the cell bodies of nitrergic nerves were affected by diabetes, we immunostained the sphenopalatine ganglia with antibodies raised against nNOS, VAChT, and PGP9.5. Two different cell types were observed: large (secretomotor) cells with a diameter of ~30–50 µm, which were positive for PGP9.5 and VAChT, and small (vasodilator) cells with a diameter of ~20–30 µm, which were positive for PGP9.5, VAChT, and nNOS (Fig. 4A). After 16 weeks of diabetes, there was a significant reduction in the number of nNOS+ small cells (Fig. 4B and C and Fig. 5A). This reduction was prevented if the insulin treatment was initiated at the 8th week (20/12 group; Fig. 4E and Fig. 5A). The nitrergic cell loss was, however, not prevented in the 20/8 group (Fig. 4D and Fig. 5A). In the 16w and 20w groups, some of the nNOS+ cells were also TUNEL+ (Fig. 4F and Fig. 5B). We did not observe any TUNEL+ cells in the control group or in the diabetic groups before 16 weeks (Fig. 5B).



View larger version (108K):
[in this window]
[in a new window]
  		FIG. 4. Nitrergic cell body loss is evident at the 20th week and is due to apoptotic cell death. A: Control group; two types of neurons were found in the sphenopalatine ganglia: nNOS+ small neurons (green) and nNOS– large neurons (indicated with white lines). The nuclei were stained using DAPI (blue) including those of fibroblasts (yellow arrow). 12w (B), 20w (C), 20/8 (D), and 20/12 (E) are shown; note the reduction in the number of nNOS+ cells. F: TUNEL+ (red) nuclei were visible in nNOS+ neurons (white arrows), nNOS– neurons (yellow arrow), and, most probably, proliferating fibroblasts (white arrowhead). Scale bar = 50 µm.

 


View larger version (28K):
[in this window]
[in a new window]
  		FIG. 5. Nitrergic cell body loss in the ganglia starts after 16 weeks and is due to apoptosis. A: nNOS+ cells in the sphenopalatine ganglia were counted in random areas manually, and the area occupied by the counted cells was measured to give the number of cells per 100,000 µm2. B: TUNEL+ cells among nNOS+ (black) and nNOS– cells (white) in the ganglia. Data are means ± SE. *P < 0.05, significantly different from control; ANOVA followed by Dunnett’s test.

 
nNOS Western blotting.
Western blotting of cerebral artery homogenates with nNOS antibody revealed a pattern of decline in nNOS protein amount throughout 20 weeks of diabetes. Western blotting of sphenopalatine ganglia homogenates showed a trend of increase by 12 weeks followed by a decrease in nNOS protein amount. The decrease in both cerebral artery and ganglia samples was prevented in the 20/12 group but not in the 20/8 group (Fig. 6).



View larger version (47K):
[in this window]
[in a new window]
  		FIG. 6. Western blot analysis of nNOS protein reveals an earlier decline in the middle cerebral arteries than in the sphenopalatine ganglia. A: Representative Western blots showing protein bands corresponding to nNOS (~160 kDa) in homogenates from middle cerebral arteries (Artery) and sphenopalatine ganglia (Ganglia). A total of 20 µg protein was loaded for each sample. Brain homogenate from a nondiabetic animal was used as the positive control (P). Each band was densitometrically quantified and expressed as a percentage of the control within the same blot. B: Pooled densitometric values from middle cerebral arteries ({blacksquare}) and ganglia ({square}) are shown at different time points. Data are means ± SE. *P < 0.05, significantly different from control; {dagger}P < 0.05, significantly different from 12w ganglia; ANOVA followed by Bonferroni’s test.

 
Smooth muscle-specific {alpha}-actin immunostaining.
To measure the smooth muscle thickness of cerebral arteries, middle cerebral arteries from each group were immunostained using an antibody raised against smooth muscle-specific {alpha}-actin. The thickness of smooth muscle layer was then measured using confocal microscopy, as shown in Fig. 7A. The thickness of the middle cerebral artery in the control group was 35.65 ± 1.25 µm, which gradually increased after 8 weeks and reached a significant level at 16 weeks (43.04 ± 1.04 µm). Insulin treatment in either the 20/8 or 20/12 groups did not affect this increase (Fig. 7B).



View larger version (58K):
[in this window]
[in a new window]
  		FIG. 7. Diabetes causes irreversible thickening of smooth muscle layer of middle cerebral arteries. Middle cerebral arteries were immunostained using smooth muscle-specific {alpha}-actin antibody. The thickness of the smooth muscle layer was measured as shown (A) in 10 random areas from each section and pooled for each group, giving mean smooth muscle thickness in micrometers (B). Data are means ± SE. *P < 0.05, significantly different from control; ANOVA followed by Dunnett’s test.

 

   DISCUSSION
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Our results demonstrated that nitrergic nerve fibers lost their nNOS content gradually throughout 20 weeks of diabetes. This decrease was reversible with insulin treatment initiated at the 8th week. However, insulin treatment begun at the 12th week was not able to reverse the nNOS depletion. This suggests that there are two phases of nNOS depletion: a first phase when the nNOS depletion is reversible and a second phase when nNOS depletion is irreversible and there is loss of axons and cell bodies.

Because the loss of PGP9.5+ and VAChT+ nerve fibers around the middle cerebral artery and the decrease in the number of nitrergic neuronal cell bodies in the sphenopalatine ganglia were observed in the second phase, the irreversible component seems to be due to degeneration of the nitrergic neurons. This is further supported by the observation of the TUNEL+ nitrergic cells in the ganglia during the second, irreversible phase, which suggests that cholinergic-nitrergic neurodegeneration occurs by apoptotic cell death. To our knowledge, this is the first demonstration of degeneration of perivascular cholinergic-nitrergic autonomic neurons innervating diabetic cerebral blood vessels.

In the reversible first phase, axons were intact but showed a significantly decreased nNOS content. The mechanism by which nNOS is depleted in the axons, but not in the cell bodies, is unclear. Previously, a deficiency in androgen (20), insulin, and/or related growth factors (21) has been suggested to cause depletion of nNOS in the distal axons of nitrergic nerves of the penis during diabetes. However, if this were the case, in the present study, a decrease in nNOS in the ganglia would also be expected. Alternatively, and perhaps most likely, axonal transport of nNOS from the cell body to the axons (22) might be compromised in diabetes. This possibility is currently under investigation in our laboratory.

The second phase was characterized by irreversible degeneration and cell body loss due to apoptosis. The neuronal cell death in this phase could be due to hyperglycemia as suggested by others for sensory nerves (22). However, the blood glucose levels of diabetic animals, which received insulin from the 12th week and had nerve loss, were comparable to nondiabetic animals. This suggests that hyperglycemia per se is unlikely to be the direct reason for autonomic neurodegeneration. More probably, advanced glycation end products (AGEs), which are known to accumulate irreversibly in the blood and tissues (i.e., delayed administration of insulin fails to lower AGE levels), are involved in this process (23,24). Indeed, we have recently shown that AGEs, but not high glucose, cause apoptosis in nNOS+ cholinergic neurons in vitro (24). We are currently investigating the accumulation of AGEs in the cerebral blood vessels and sphenopalatine ganglia of diabetic rats.

We have recently made a similar observation of biphasic degeneration of nitrergic nerve fibers in diabetic penis and pyloric sphincter (17). Together with the present findings, these suggest a novel mechanism for degeneration of nitrergic autonomic nerves during diabetes. The model we are proposing suggests that nitrergic nerves degenerate in two phases during diabetes. In the first phase, possibly because of a defective axonal transport, nNOS is depleted in the axons (nerve fibers) while its concentration remains unchanged or slightly elevated in the neuronal cell bodies (ganglia). This phase is reversible with insulin treatment. In the second phase, the accumulation of nNOS protein in the proximal axon and the cell body coincides with the accumulation of AGEs, which results in increased oxidative stress and activation of caspase signaling pathways in the cell body leading to apoptosis (24). It is not known whether other nitrergic nerves in the body such as those innervating the heart and coronary arteries are similarly affected in both types of diabetes. Nevertheless, our biphasic model highlights the importance of blood glucose control in the prevention of diabetic complications, since uncontrolled blood glucose levels leading to AGE accumulation and neurodegeneration would result in irreversible damage.

Another plausible mechanism for the apoptotic death of the nitrergic neurons in the second phase could involve N-methyl-D-aspartate (NMDA) receptors whose mRNA is expressed in several autonomic ganglia, including sphenopalatine ganglia (25). Exogenous application of NMDA relaxes cerebral blood vessels via activation of nNOS, suggesting that NMDA receptors might be involved in activation of autonomic nitrergic nerves (26,27). NMDA receptor activation has been suggested to induce neuronal apoptosis in an NO-dependent manner (28). Moreover, NMDA receptor subunits in the central neurons are modified transcriptionally and post-translationally by diabetes (29). Therefore, abnormal signaling through modified NMDA receptors might alter NO production in the ganglia, leading to apoptosis in diabetes.

The implications of this biphasic model are twofold. First, the model suggests "a point of no return" after which the nitrergic neurons are lost irreversibly. This emphasizes the importance of early intervention and indicates that new treatment options for autonomic neuropathy are needed for patients who pass this point. Such treatments such as AGE-crosslink breakers should be able to arrest the pathology and preserve the existing function. Second, new diagnostic approaches that will detect nitrergic nerve function and integrity need to be developed to assess whether a diabetic patient has reached this point.

Perivascular nitrergic nerves around the cerebral arteries have been shown to contain other neurotransmitters such as vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) (12). Interestingly, earlier studies suggested a reduction of VIP-ergic nerve fibers in the cerebral blood vessels of STZ-induced diabetic rats (30). Our study, showing that the nitrergic nerve fibers undergo a biphasic degenerative process during diabetes, highlights the relevance of those early studies.

We used the middle cerebral artery because the axons around this vessel showed the most consistent nNOS immunostaining among all of the cerebral vessels studied. It would be of high interest to study the neurotransmitter content of the axons around all cerebral arteries in diabetes to determine in which vessels the loss of nNOS is most likely to contribute to the pathogenesis of stroke.

In the current study, we have shown two different cell types in the sphenopalatine ganglia: large nNOS– cells and small nNOS+ cells. This is in accordance with a previous study where the size and the targets of nerve cells in the cat sphenopalatine ganglion were investigated (31). The study suggested that the large cells are secretomotor neurons innervating the palatine glands, whereas small cells are vasodilator cells innervating the cerebral vasculature (31). In our study, we have shown that the small vasodilator neurons are nNOS+. We have also demonstrated that large nNOS– neurons underwent apoptosis in diabetic animals, although not to the same extent as the nitrergic neurons. It is known that besides the palatine salivary glands, the sphenopalatine ganglion also innervates lacrimal glands and vasculature in the orbit (32,33). Our results therefore might suggest a pathophysiological mechanism by which autonomic neuropathy could be involved in xerostomia (34), glaucoma (35), and decreased lacrimation (36) observed in diabetic patients.

NO is released not only by nitrergic nerves but also by the endothelial cells in the cerebral arteries. Both types of diabetes have been shown to impair endothelial NO-dependent relaxation of cerebral blood vessels (37–41) while vasoconstrictor responses are preserved (42). Together with our findings, these studies suggest an overall reduction in neurogenic and endothelial NO-dependent vasodilation in diabetic cerebral arteries, which could contribute to the cerebrovascular pathologies associated with diabetes.

Interestingly, the thickness of the smooth muscle layer of the middle cerebral artery increased gradually after 12 weeks of diabetes. Although we did not observe any increase in the number of smooth muscle cells to cause the thickening, this could be due to the technique we used for this measurement. Therefore, we are not certain whether the increase in smooth muscle layer thickness is due to hyperplasia or hypertrophy of smooth muscle cells. Moreover, we did not use planimetry to measure the area occupied by the smooth muscle cells, which is more accurate than measuring the thickness. Therefore, these results should be interpreted with caution. The thickening of smooth muscle layer could be another factor in the pathogenesis of diabetic stroke, as suggested previously (43). Deficiency of endogenous vasodilator substances such as NO or sympathetic denervation could account for enhanced growth of smooth muscle cells (44,45).

In conclusion, our biphasic nitrergic nerve degeneration model suggests a significant decrease in the nNOS protein during diabetes. Together with endothelial dysfunction, this could result in severe deficiency of NO and vasodilation response to both nerve stimulation and shear stress in cerebral arteries. This might further lead to thickening of smooth muscle layer and an increase in vasoconstrictor response. The imbalance between dilatory and constrictive aspects might eventually increase the susceptibility to strokes.


   ACKNOWLEDGMENTS
 
This work was funded by Juvenile Diabetes Research Foundation International.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Address correspondence and reprint requests to S. Cellek, MD, PhD, Wolfson Institute for Biomedical Research, University College London, Gower St., Cruciform Building, London WC1E 6BT, U.K. E-mail: s.cellek{at}ucl.ac.uk

Received for publication July 7, 2004 and accepted in revised form October 4, 2004

Abbreviations: AGE, advanced glycation end product; FITC, fluorescein isothiocyanate; NMDA, N-methyl-D-aspartate; nNOS, neuronal nitric oxide synthase; STZ, streptozotocin; TUNEL, Tdt-mediated dUTP nick-end labeling; VAChT, vesicular acetylcholine transporter


   REFERENCES
TOP
 ABSTRACT
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke22 :312 –318,1991[Abstract/Free Full Text]
  2. Neaton JD, Wentworth DN, Cutler J, Stamler J, Kuller L: Risk factors for death from different types of stroke: Multiple Risk Factor Intervention Trial Research Group. Ann Epidemiol3 :493 –499,1993[Medline]
  3. Warlow CP: Epidemiology of stroke. Lancet352 (Suppl. 3) :SIII1 –SIII4,1998
  4. Fuller JH, Stevens LK, Wang SL: Risk factors for cardiovascular mortality and morbidity: the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia44 (Suppl. 2) :S54 –S64,2001
  5. Cohen JA, Estacio RO, Lundgren RA, Esler AL, Schrier RW: Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci108 :73 –78,2003[Medline]
  6. Toda N, Okamura T: The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. Pharmacol Rev55 :271 –324,2003[Abstract/Free Full Text]
  7. Toda N: Mediation by nitric oxide of neurally-induced human cerebral artery relaxation. Experientia49 :51 –53,1993[Medline]
  8. Moncada S, Higgs A, Furchgott R: International Union of Pharmacology Nomenclature in Nitric Oxide Research. Pharmacol Rev49 :137 –142,1997[Abstract/Free Full Text]
  9. Nozaki K, Moskowitz MA, Maynard KI, Koketsu N, Dawson TM, Bredt DS, Snyder SH: Possible origins and distribution of immunoreactive nitric oxide synthase-containing nerve fibers in cerebral arteries. J Cereb Blood Flow Metab13 :70 –79,1993[Medline]
  10. Minami Y, Kimura H, Aimi Y, Vincent SR: Projections of nitric oxide synthase-containing fibers from the sphenopalatine ganglion to cerebral arteries in the rat. Neuroscience60 :745 –759,1994[Medline]
  11. Toda N, Ayajiki K, Tanaka T, Okamura T: Preganglionic and postganglionic neurons responsible for cerebral vasodilation mediated by nitric oxide in anesthetized dogs. J Cereb Blood Flow Metab20 :700 –708,2000[Medline]
  12. Edvinsson L, Elsas T, Suzuki N, Shimizu T, Lee TJ: Origin and co-localization of nitric oxide synthase, CGRP, PACAP, and VIP in the cerebral circulation of the rat. Microsc Res Tech53 :221 –228,2001[Medline]
  13. Morita-Tsuzuki Y, Hardebo JE, Bouskela E: Inhibition of nitric oxide synthase attenuates the cerebral blood flow response to stimulation of postganglionic parasympathetic nerves in the rat. J Cereb Blood Flow Metab13 :993 –997,1993[Medline]
  14. Goadsby PJ, Uddman R, Edvinsson L: Cerebral vasodilatation in the cat involves nitric oxide from parasympathetic nerves. Brain Res707 :110 –118,1996[Medline]
  15. Ignacio CS, Curling PE, Childres WF, Bryan RM Jr: Nitric oxide-synthesizing perivascular nerves in the rat middle cerebral artery. Am J Physiol273 :R661 –R668,1997
  16. Cellek S, Rodrigo J, Lobos E, Fernandez P, Serrano J, Moncada S: Selective nitrergic neurodegeneration in diabetes mellitus: a nitric oxide-dependent phenomenon. Br J Pharmacol128 :1804 –1812,1999[Medline]
  17. Cellek S, Foxwell NA, Moncada S: Two phases of nitrergic neuropathy in streptozotocin-induced diabetic rats. Diabetes52 :2353 –2362,2003[Abstract/Free Full Text]
  18. Herbison AE, Simonian SX, Norris PJ, Emson PC: Relationship of neuronal nitric oxide synthase immunoreactivity to GnRH neurons in the ovariectomized and intact female rat. J Neuroendocrinol8 :73 –82,1996[Medline]
  19. Stone LS, Vulchanova L, Riedl MS, Wang J, Williams FG, Wilcox GL, Elde R: Effects of peripheral nerve injury on alpha-2A and alpha-2C adrenergic receptor immunoreactivity in the rat spinal cord. Neuroscience93 :1399 –1407,1999[Medline]
  20. Vernet D, Cai L, Garban H, Babbitt ML, Murray FT, Rajfer J, Gonzalez-Cadavid NF: Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology136 :5709 –5717,1995[Abstract]
  21. Abdelbaky TM, Brock GB, Huynh H: Improvement of erectile function in diabetic rats by insulin: possible role of the insulin-like growth factor system. Endocrinology139 :3143 –3147,1998[Abstract/Free Full Text]
  22. Russell JW, Sullivan KA, Windebank AJ, Herrmann DN, Feldman EL: Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis6 :347 –363,1999[Medline]
  23. Rodriguez-Manas L, Angulo J, Vallejo S, Peiro C, Sanchez-Ferrer A, Cercas E, Lopez-Doriga P, Sanchez-Ferrer CF: Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature. Diabetologia46 :556 –566,2003[Medline]
  24. Cellek S, Qu W, Schmidt AM, Moncada S: Synergistic action of advanced glycation end products and endogenous nitric oxide leads to neuronal apoptosis in vitro: a new insight into selective nitrergic neuropathy in diabetes. Diabetologia47 :331 –339,2004[Medline]
  25. Shigemoto R, Ohishi H, Nakanishi S, Mizuno N: Expression of the mRNA for the rat NMDA receptor (NMDAR1) in the sensory and autonomic ganglion neurons. Neurosci Lett144 :229 –232,1992[Medline]
  26. Faraci FM, Brian JE Jr: 7-Nitroindazole inhibits brain nitric oxide synthase and cerebral vasodilatation in response to N-methyl-D-aspartate. Stroke26 :2172 –2175,1995[Abstract/Free Full Text]
  27. Faraci FM, Breese KR: Nitric oxide mediates vasodilatation in response to activation of N-methyl-D-aspartate receptors in brain. Circ Res72 :476 –480,1993[Abstract/Free Full Text]
  28. Rameau GA, Chiu LY, Ziff EB: Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-D-aspartate receptor. J Biol Chem279 :14307 –14314,2004[Abstract/Free Full Text]
  29. Di Luca M, Ruts L, Gardoni F, Cattabeni F, Biessels GJ, Gispen WH: NMDA receptor subunits are modified transcriptionally and post-translationally in the brain of streptozotocin-diabetic rats. Diabetologia42 :693 –701,1999[Medline]
  30. Lagnado ML, Crowe R, Lincoln J, Burnstock G: Reduction of nerves containing vasoactive intestinal polypeptide and serotonin, but not neuropeptide Y and catecholamine, in cerebral blood vessels of the 8-week streptozotocin-induced diabetic rat. Blood Vessels24 :169 –180,1987[Medline]
  31. Kuchiiwa S, Cheng SB, Kuchiiwa T: Morphological distinction between vasodilator and secretomotor neurons in the pterygopalatine ganglion of the cat. Neurosci Lett288 :219 –222,2000[Medline]
  32. Kuchiiwa S: Intraocular projections from the pterygopalatine ganglion in the cat. J Comp Neurol300 :301 –308,1990[Medline]
  33. Hara H, Zhang QJ, Kuroyanagi T, Kobayashi S: Parasympathetic cerebrovascular innervation: an anterograde tracing from the sphenopalatine ganglion in the rat. Neurosurgery32 :822 –827,1993[Medline]
  34. Meurman JH, Collin HL, Niskanen L, Toyry J, Alakuijala P, Keinanen S, Uusitupa M: Saliva in non-insulin-dependent diabetic patients and control subjects: the role of the autonomic nervous system. Oral Surg Oral Med Oral Pathol Oral Radiol Endod86 :69 –76,1998[Medline]
  35. Bonovas S, Peponis V, Filioussi K: Diabetes mellitus as a risk factor for primary open-angle glaucoma: a meta-analysis. Diabet Med21 :609 –614,2004[Medline]
  36. Moss SE, Klein R, Klein BE: Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol118 :1264 –1268,2000[Abstract/Free Full Text]
  37. Mayhan WG: Impairment of endothelium-dependent dilatation of cerebral arterioles during diabetes mellitus. Am J Physiol256 :H621 –H625,1989
  38. Mayhan WG: Impairment of endothelium-dependent dilatation of the basilar artery during diabetes mellitus. Brain Res580 :297 –302,1992[Medline]
  39. Fujii K, Heistad DD, Faraci FM: Effect of diabetes mellitus on flow-mediated and endothelium-dependent dilatation of the rat basilar artery. Stroke23 :1494 –1498,1992[Abstract/Free Full Text]
  40. Erdos B, Miller AW, Busija DW: Impaired endothelium-mediated relaxation in isolated cerebral arteries from insulin-resistant rats. Am J Physiol Heart Circ Physiol282 :H2060 –H2065,2002[Abstract/Free Full Text]
  41. Schwaninger RM, Sun H, Mayhan WG: Impaired nitric oxide synthase-dependent dilatation of cerebral arterioles in type II diabetic rats. Life Sci73 :3415 –3425,2003[Medline]
  42. Mayhan WG: Constrictor responses of the rat basilar artery during diabetes mellitus. Brain Res783 :326 –331,1998[Medline]
  43. Mavrikakis ME, Sfikakis PP, Kontoyannis D, Horti M, Kittas C, Koutras DA, Raptis SA: Macrovascular disease of coronaries and cerebral arteries in streptozotocin-induced diabetic rats: a controlled, comparative study. Exp Clin Endocrinol Diabetes106 :35 –40,1998
  44. Dzau VJ: The role of mechanical and humoral factors in growth regulation of vascular smooth muscle and cardiac myocytes. Curr Opin Nephrol Hypertens2 :27 –32,1993[Medline]
  45. Dimitriadou V, Aubineau P, Taxi J, Seylaz J: Ultrastructural changes in the cerebral artery wall induced by long-term sympathetic denervation. Blood Vessels25 :122 –143,1988[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cellek, S.
Right arrow Articles by Foxwell, N. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cellek, S.
Right arrow Articles by Foxwell, N. A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum